Skip to search formSkip to main contentSkip to account menu

TransCyte

Known as: Dermagraft-TC 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Coated Materials, Biocompatible

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Aetna considers TransCyte experimental and investigational for all other indications because its effe for indications other than the ones listed above has not been established.
2014
2014
Tissue Engineering for Wound and Organ Repair: Angiogenesis as a Mechanism of Action
Over the last two decades, skin substitutes have been developed which have found application in the treatment of acute and… 
Review
2012
Review
2012
Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?
Although much progress has been made regarding our knowledge of stem cells and their potential applications for therapeutic… 
2009
2009
LETTER TO THE EDITOR Protocols for the Surgical Management of Burn Injury: Has Their Development Been Worthwhile?
Dear Sir, Surgical protocols were introduced by the Adult Burn Service, Royal Adelaide Hospital, in early 2005,1 documenting… 
2008
2008
156 Homocysteine Associated with Impaired Wound Healing and Decreased Nitric Oxide Production
Nitric oxide (NO) is a critical mediator of normal tissue repair and is inhibited by homocysteine (Hcy). Following 8 weeks of… 
Review
2002
Review
2002
The Use of Dermagraft in Neuropathic Foot Ulcers in People with Diabetes: An Economic Analysis for Australia
® , a living human dermal replacement, as an adjunct therapy. The cost of conventional management of foot ulcers was established… 
2001
2001
FDA approves Dermagraft® for diabetic foot ulcers
2000
2000
Safety and efficacy of TransCyte for the treatment of partial-thickness burns.
2000
2000
Safety and efficacy of TransCyte for the treatment of partial-thickness burns.
2000
2000
Management of superficial partial and indeterminate depth burns- comparative study of transcyte against biobrane and silvazine plus dressings.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)